Oxurion NV (EBR: OXUR)

Market Cap	2.67M
Revenue (ttm)	263.00K
Net Income (ttm)	-18.97M
Shares Out	1.34M
EPS (ttm)	-114.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,983
Open	1.010
Previous Close	2.000
Day's Range	1.000 - 1.080
52-Week Range	1.000 - 18.000
Beta	0.58
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 6, 2024

About Oxurion NV

Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness. It focuses on developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1991
• Employees: 20
• Stock Exchange: Euronext Brussels
• Ticker Symbol: OXUR

Financial Performance

In 2023, Oxurion NV's revenue was 263,000, a decrease of -55.80% compared to the previous year's 595,000. Losses were -18.97 million, -40.13% less than in 2022.